Glenmark gets FDA nod for generic Faslodex
Glenmark Pharmaceuticals has received the Food and Drug Administration’s green light for fulvestrant injection, a generic of AstraZeneca's Faslodex injection. The drug will be available in a dosage strength of 250 mg/5 mL (50 mg/mL).
Faslodex injection, 250 mg/5 mL (50 mg/mL) had a market value of approximately $549.9 million for the 12 month period ended June 2019, according to IQVIA.
Glenmark said its portfolio currently consists of 159 products authorized for distribution, as well as 56 abbreviated new drug applications whose approval is pending with the FDA.
Faslodex injection, 250 mg/5 mL (50 mg/mL) had a market value of approximately $549.9 million for the 12 month period ended June 2019, according to IQVIA.
Glenmark said its portfolio currently consists of 159 products authorized for distribution, as well as 56 abbreviated new drug applications whose approval is pending with the FDA.